Aflibercept/bevacizumab/triamcinoloneLack of efficacy during treatment of macular oedema secondary to central retinal vein occlusion: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2022年 / 1896卷 / 1期
关键词：
D O I：
10.1007/s40278-022-10817-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：26 / 26
相关论文
共 50 条
  • [21] Aflibercept in macular oedema secondary to retinal vein occlusion refractory to previous bevacizumab or ranibizumab: 48 week outcomes
    Spooner, Kimberly
    Fraser-Bell, Samantha
    Hong, Thomas
    Chang, Andrew
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 47 : 155 - 156
  • [22] Real world results of aflibercept treatment for macular oedema secondary to central retinal vein occlusions
    Ali, Zaria
    Aslam, Tariq Mehmood
    Bailey, Caroline
    Chhabra, Ramandeep
    Stone, Amy
    D'Souza, Yvonne
    Mahmood, Sajjad
    Balaskas, Konstantinos
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [23] Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
    Becky Pennington
    Abualbishr Alshreef
    Laura Flight
    Andrew Metry
    Edith Poku
    Philip Hykin
    Sobha Sivaprasad
    A. Toby Prevost
    Joana C. Vasconcelos
    Caroline Murphy
    Joanna Kelly
    Yit Yang
    Andrew Lotery
    Michael Williams
    John Brazier
    PharmacoEconomics, 2021, 39 : 913 - 927
  • [24] Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
    Pennington, Becky
    Alshreef, Abualbishr
    Flight, Laura
    Metry, Andrew
    Poku, Edith
    Hykin, Philip
    Sivaprasad, Sobha
    Prevost, A. Toby
    Vasconcelos, Joana C.
    Murphy, Caroline
    Kelly, Joanna
    Yang, Yit
    Lotery, Andrew
    Williams, Michael
    Brazier, John
    PHARMACOECONOMICS, 2021, 39 (08) : 913 - 927
  • [25] A retrospective comparison of aflibercept and ranibizumab in the management of macular oedema secondary to retinal vein occlusion
    Di Simplicio, Sandro
    Hogg, Jeff
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [26] Intravitreal Aflibercept (Eylea®): A Review of Its Use in Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion
    Lily P. H. Yang
    Kate McKeage
    Drugs & Aging, 2014, 31 : 395 - 404
  • [27] Intravitreal Aflibercept (Eylea®): A Review of Its Use in Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion
    Yang, Lily P. H.
    McKeage, Kate
    DRUGS & AGING, 2014, 31 (05) : 395 - 404
  • [28] Bevacizumab for treatment of macular edema secondary to retinal vein occlusion
    Jaissle, G. B.
    Ziemssen, F.
    Petermeier, K.
    Szurman, P.
    Ladewig, M.
    Gelisken, F.
    Voelker, M.
    Holz, F. G.
    Bartz-Schmidt, K. U.
    OPHTHALMOLOGE, 2006, 103 (06): : 471 - 475
  • [29] Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
    Schaal, K. B.
    Hoeh, A. E.
    Scheuerle, A.
    Schuett, F.
    Dithmar, S.
    OPHTHALMOLOGE, 2007, 104 (04): : 285 - 289
  • [30] Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion
    Cheng, K-C
    Wu, W-C
    Chen, K-J
    EYE, 2009, 23 (11) : 2024 - 2032
12345